ENDEAVOR IV Trial Results Presented At TCT 2007

Late-breaking results from the ENDEAVOR IV trial, presented at TCT 2007, the annual scientific symposium of the Cardiovascular Research Foundation, show that the Endeavor zotarolimus-eluting stent met the trial’s primary endpoint, demonstrating a similar overall safety profile (equivalent rates of death, heart attack, and repeat procedures) to the Taxus paclitaxel-eluting stent at 1 year. [click link for full article]

More: continued here

Filed under: Clinical Trials on October 25th, 2007